Drug-eluting nasal implants: formulation, characterization, clinical applications and challenges

Area of Science:

• Otolaryngology
• Biomaterials Science
• Pharmacology

Background:

• Chronic rhinosinusitis (CRS) significantly impairs quality of life due to persistent sinus inflammation and infection.
• Treatment challenges include adhesions, ostial stenosis, and recurrent infections, necessitating advanced therapeutic strategies.
• Drug-eluting implants are emerging as a viable alternative to conventional CRS treatments.

Purpose of the Study:

• To review potential drug candidates for nasal implants used in CRS treatment.
• To discuss formulation, optimization, and characterization methods for these implants.
• To evaluate clinical applications, advantages, limitations, and future directions in nasal drug implant development.

Main Methods:

• Literature review of potential drug candidates for nasal implants.
• Analysis of formulation and characterization techniques for drug delivery systems.
• Examination of clinical data and case studies for approved nasal implants.
• Discussion of challenges and future research needs in the field.

Main Results:

• Several drug candidates show potential for nasal implant applications in CRS.
• Various formulation and characterization methods are available for optimizing drug release and efficacy.
• Clinically-approved implants like Propel™, Relieva stratus™ MicroFlow spacer, and Sinu-Foam™ spacer offer benefits but have limitations.
• The review highlights the need for further research into novel drug implant designs and clinical validation.

Conclusions:

• Drug-eluting nasal implants represent a promising therapeutic avenue for managing chronic rhinosinusitis.
• Optimized formulations and rigorous characterization are crucial for effective drug delivery and patient outcomes.
• Continued research and clinical investigation are essential to overcome current limitations and advance the field of nasal drug implants for CRS.